"Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration"

• Register: EUCTR
• Last refreshed on: 19 March 2012
• Main ID: EUCTR2005-002135-27-IT
• Date of registration: 28/06/2005
• Prospective Registration: Yes
• Primary sponsor: ISTITUTO GIANNINA GASLINI
• Public title: "Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration"
• Scientific title: "Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration"
• Date of first enrolment: 06/07/2005
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002135-27
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: Single blind: Double blind: Parallel group: Cross over: Other: If controlled, specify comparator, Other Medicinial Product: Placebo: Other:

Countries of recruitment

Italy

Key inclusion & exclusion criteria

Inclusion criteria:
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Cystic Fibrosis patients with glucose intolerance
MedDRA version: 6.1 Level: PT Classification code 10011762

Intervention(s)

Trade Name: LANTUS*SC 5CAR3ML100UI/ML
Product Name: NA
Product Code: NA
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Insulin glargine
Concentration unit: IU international unit(s)
Concentration type: equal
Concentration number: 300-

Primary Outcome(s)

Secondary Objective:

Primary end point(s):

Main Objective:

Secondary ID(s)

IGG-FC-G-01